INJ vs. INJC: Injective (INJ)compares direct token holding with ETF shares

News

Injective (INJ)outlines the differences between holding INJ directly and owning INJC ETF shares, including custody, staking, access and costs.

Injective (INJ)has published a side-by-side comparison of direct INJ ownership and shares of the Canary Staked INJ ETF, framing the choice as one between self-custodied token exposure and brokerage-account access. The guide says INJ holders keep the token in a wallet or exchange account, while INJC investors own fund shares held in a brokerage account, with staking built into the product structure.

Evidence and context

According to the Oct. 14, 2026 guide from Injective, INJ is the network’s native asset and is used to pay fees, stake to secure the chain and vote on upgrades. The company says direct holders control their own keys, can choose a validator and can use INJ across Injective apps, while INJC holders do not vote, do not move tokens onchain and cannot redeem shares for INJ. The guide adds that the fund’s custodian is BitGo and that the fund stakes part of its INJ while keeping some unstaked to meet redemptions.

Injective’s comparison also separates the trading venues and cost structures. INJ trades 24/7 on crypto venues, while INJC trades on Nasdaq during market hours. The guide says direct INJ holders may face exchange fees, network withdrawal fees and validator commission if staking, while INJC investors face a sponsor fee charged as an annual percentage of assets, staking-related fees taken from rewards and any brokerage commission or bid-ask spread. The guide does not provide a fee rate for the ETF in the supplied material.

The fund’s pricing mechanism is another key distinction. Injective says one INJC share does not equal one INJ token and that the fund values its INJ holdings each trading day using the CoinDesk Injective rate at 4:00 p.m. ET to determine net asset value. During the session, shares can trade above or below that value depending on supply and demand, and the amount of INJ backing each share can change as fees are paid and staking rewards are added. The company says the fund holds spot INJ, does not use leverage or futures, and does not pass through airdrops or forked assets.

The comparison comes as INJ traded at $7.72 on Oct. 14, 2026, down 4.86% over 24 hours, with a market capitalization of $771.77 million, according to the provided market data. Recent Injective-related announcements include the Oct. 8, 2026 addition of Gulf Labs, part of Thailand’s GULF Group, as an Injective validator, and a Sept. 17, 2026 announcement that INJ became live on Solana. Those disclosures provide context for the network’s ongoing expansion but do not change the mechanics described in the ETF-versus-token guide.

Staking, custody and operational limits

The guide says direct INJ staking requires the holder to choose a validator, and the broader background material notes that staking rewards vary and are not guaranteed. The same background also says unstaking requires a 21-day unbonding period during which tokens cannot be transferred and earn no staking rewards. For INJC, the fund manages unbonding internally, and investors simply sell shares if they want to exit. The guide says holders should not expect to move fund shares into a wallet.

Injective’s material also highlights limits that matter for different users. Direct INJ may be preferred by those who want to participate in governance, stake independently or use the token inside the Injective ecosystem. INJC is positioned for investors who want exposure through an existing brokerage account without handling private keys or staking operations themselves. The guide says eligibility depends on the broker, account type and jurisdiction, and that retirement-account access is up to the broker.

The available material includes a dated risk note from a Canary filing stating that the proportion forfeited under Injective’s slashing parameters was zero as of Sept. 15, 2026. That figure is date-specific and should not be read as a guarantee that slashing risk is absent or unchanged, because governance can alter validator rules and penalties can still apply to past validator misconduct.

Overall, the comparison is less a ranking than a custody choice: INJ gives holders direct token functionality, while INJC packages exposure inside a listed fund with its own pricing, fees and operational constraints. The timing of any further changes to the ETF or to Injective’s staking mechanics was not supplied in the source material.